Compare ALEMBIC PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 15.6 10.2 153.8% View Chart
P/BV x 3.9 1.9 207.1% View Chart
Dividend Yield % 1.0 0.6 174.9%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
AUROBINDO PHARMA
Mar-19
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs664830 80.0%   
Low Rs412527 78.2%   
Sales per share (Unadj.) Rs208.7333.9 62.5%  
Earnings per share (Unadj.) Rs31.040.4 76.8%  
Cash flow per share (Unadj.) Rs37.151.8 71.7%  
Dividends per share (Unadj.) Rs5.502.50 220.0%  
Dividend yield (eoy) %1.00.4 277.4%  
Book value per share (Unadj.) Rs144.2237.1 60.8%  
Shares outstanding (eoy) m188.52585.91 32.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.0 126.9%   
Avg P/E ratio x17.416.8 103.3%  
P/CF ratio (eoy) x14.513.1 110.6%  
Price / Book Value ratio x3.72.9 130.4%  
Dividend payout %17.76.2 286.4%   
Avg Mkt Cap Rs m101,461397,569 25.5%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m7,46725,849 28.9%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m39,347195,636 20.1%  
Other income Rs m941,553 6.0%   
Total revenues Rs m39,441197,189 20.0%   
Gross profit Rs m8,73639,519 22.1%  
Depreciation Rs m1,1526,680 17.3%   
Interest Rs m1842,626 7.0%   
Profit before tax Rs m7,49331,767 23.6%   
Minority Interest Rs m1127 40.0%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1,5687,269 21.6%   
Profit after tax Rs m5,84423,645 24.7%  
Gross profit margin %22.220.2 109.9%  
Effective tax rate %20.922.9 91.4%   
Net profit margin %14.912.1 122.9%  
BALANCE SHEET DATA
Current assets Rs m19,577153,645 12.7%   
Current liabilities Rs m14,896120,429 12.4%   
Net working cap to sales %11.917.0 70.1%  
Current ratio x1.31.3 103.0%  
Inventory Days Days90135 66.4%  
Debtors Days Days4564 71.2%  
Net fixed assets Rs m27,097103,909 26.1%   
Share capital Rs m377586 64.3%   
"Free" reserves Rs m26,811138,322 19.4%   
Net worth Rs m27,188138,908 19.6%   
Long term debt Rs m4,9931,800 277.5%   
Total assets Rs m47,778264,544 18.1%  
Interest coverage x41.713.1 318.4%   
Debt to equity ratio x0.20 1,417.6%  
Sales to assets ratio x0.80.7 111.4%   
Return on assets %12.69.9 127.0%  
Return on equity %21.517.0 126.3%  
Return on capital %23.623.8 99.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45397,316 20.0%   
Fx outflow Rs m6,06540,589 14.9%   
Net fx Rs m13,38856,727 23.6%   
CASH FLOW
From Operations Rs m8,12016,220 50.1%  
From Investments Rs m-7,556-28,768 26.3%  
From Financial Activity Rs m59019,191 3.1%  
Net Cashflow Rs m1,1536,656 17.3%  

Share Holding

Indian Promoters % 74.1 54.1 137.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 8.0 36.5%  
FIIs % 9.1 27.7 32.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.2 136.3%  
Shareholders   49,328 69,601 70.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALKEM LABORATORIES  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON   

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Dec 6, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS